Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
circular RNA BCMA CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Cartesian Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Cartesian Therapeutics is developing circular RNA (circRNA) engineered CAR-T cells targeting B-cell maturation antigen (BCMA). This platform utilizes circular RNA templates to drive transient CAR expression in T cells, avoiding the permanent genomic modification associated with viral vectors. Circular RNA is inherently more stable than linear mRNA due to its resistance to exonucleolytic degradation, which results in more sustained CAR expression and enhanced therapeutic potency. Preclinical studies in multiple myeloma models have demonstrated that the circular RNA format allows for deeper tumor regression and improved pharmacokinetics compared to linear mRNA-based CAR-T cells (such as Descartes-08). The therapy is being explored for both oncology and autoimmune indications, such as myasthenia gravis, and does not require lymphodepletion.
- Other names
- circRNA BCMA CAR-Tcircular RNA-encoded BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on circular RNA BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on circular RNA BCMA CAR-T cells.